Background: Our aim was to assess serum levels of the soluble receptor for advanced glycation end products (sRAGE) and to examine their association with anthropometric and metabolic parameters in patients with prediabetes and obese controls.
Methods: The two study groups were composed of 42 patients with prediabetes and diabetic neuropathy and 42 age-, gender-, body weight (BW)-, and body mass index (BMI)-matched obese adults as the control group. Prediabetes was diagnosed by the following criteria issued by the American Diabetes Association: impaired fasting glucose [fasting plasma glucose (FPG) level of 100-125 mg/dL], impaired glucose tolerance (2 hr plasma glucose level of 140-199 mg/dL after a 75 grams oral glucose challenge), or a glycated hemoglobin (HbA1C) level of 5.7%-6.4%.
Results: There were no differences between the groups in terms of age, gender distribution, BW, or BMI. Despite these similarities, patients with prediabetes had higher FPG, HbA1c, and 2-hr postchallenge glucose levels, higher systolic and diastolic blood pressure, and larger waist and hip circumferences compared with the obese controls. Lipid measurements, complete blood counts, kidney and liver function tests, high-sensitivity C-reactive protein, and sRAGE levels were similar between the two groups. We found significant negative correlations between sRAGE levels and BW, BMI, waist and hip circumferences, waist-to-hip ratios, and low-density lipoprotein (LDL) cholesterol levels. There were no significant correlations with other parameters, including demographic, metabolic, and blood pressure measurements.
Conclusions: In contrast to glycemic parameters, serum levels of sRAGE were negatively correlated with body measurements indicative of obesity in the prediabetic state. In addition, the negative correlation with LDL cholesterol levels suggests that sRAGE has a more robust association with metabolic syndrome than with prediabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/met.2015.0078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Insomnia is a modifiable risk factor for type 2 diabetes.
Objective: Describe the methodology for the Sleep for Health study, a randomized clinical trial examining the effectiveness of digital cognitive behavioral therapy for insomnia (dCBT-I) in reducing hyperglycemia in 300 people with both insomnia and prediabetes.
Outcomes: Primary outcome is glucose level 2 h after a 75-g glucose load.
First Reported Case of Hemoglobin Graz in the United States: Implications for Misleading Hemoglobin A Results.
JCEM Case Rep
January 2025
Department of Endocrinology, St. Luke's University Health Network, Bethlehem, PA 18015, USA.
Routine serum studies in a female patient with sustained prediabetic glycated hemoglobin A (HbA) levels, controlled on metformin, yielded an unexpected finding: an elevated HbA value of ≥14.9% (≥139 mmol/mol) (normal reference range, <5.7% to <39 mmol/mol).
View Article and Find Full Text PDFEfficacy of antiobesity medications for weight reduction in older adults: a systematic review.
Obesity (Silver Spring)
December 2024
Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Objective: The objective of this study was to examine weight reduction and adverse events associated with use of antiobesity medications (AOMs) in older adults ages ≥65 years.
Methods: Seven databases were searched for studies evaluating weight reduction of Food and Drug Administration (FDA)-approved AOMs. Studies had to include adults ages ≥65 years with obesity (BMI ≥ 30 kg/m or ≥27 kg/m with one weight-related condition), with independent analysis of weight reduction for adults ages ≥65 years.
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
Eur J Heart Fail
December 2024
Baylor Scott and White Research Institute, Dallas, TX, USA, and Department of Medicine, University of Mississippi, Jackson, MS, USA.
Aims: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2 diabetes mellitus (T2DM) in acute MI trials are sparse. The treatment effect of empagliflozin in those with and without T2DM in acute MI is unknown.
View Article and Find Full Text PDFInterpersonal Continuity of Care May Help Delay Progression to Type 2 Diabetes.
J Am Board Fam Med
December 2024
From the Department of Population Health Sciences, Geisinger, Danville, PA (BLJ, LBD); Center for Obesity and Metabolic Health, Danville, PA (GCW, AC, CDS, LBD); Department of Health Services Research, Management and Policy, University of Florida, Health Sciences Center, Gainesville, FL (AGM); Geisinger Department of Genomic Health, Danville, PA 17822 (AKR); Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD (AKR).
Background: The association between interpersonal continuity of care (CoC) and progression from the prediabetic state to Type 2 Diabetes (T2D) remains unknown.
Aim: To evaluate the association between interpersonal CoC and the progression to T2D among persons with prediabetes.
Design And Setting: A retrospective cohort study using electronic health record (EHR) data from 6620 patients at Geisinger, a large rural health care system in Danville, PA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!